| 
            Only notified under the "contained use" procedure. Dossier submitted on 10/06/2003.           | 
                  
            A phase 1 randomized, placebo-controlled, double-blind, dose escalation trial to evaluate the safety and immunogenicity of tgAAC09, a gag-PR-DRT AAV HIV vaccine           | 
                  
                  
            Humans           | 
                  
            genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1           |